DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy

Tuesday, Aug. 31st 2010 6:14 AM

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application.

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy, 5.0 out of 5 based on 1 rating
Posted on Tuesday, Aug. 31st 2010 6:14 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply